Melanoma Stage Iv, Unresectable Stage III Melanoma
Conditions
Keywords
Melanoma, Fecal Microbiota Transplantation, Immunotherapy
Brief summary
Altering the Gut Microbiota of Melanoma Patients Who Failed Immunotherapy Using Fecal Microbiota Transplantation (FMT) From Responding Patients. FMT includes both colonoscopy and stool capsules.
Detailed description
This is a phase I single-center study of fecal microbiota transplant (FMT) in melanoma patients who failed at least one line of PD-1 blockade. Eligible patients must have a disease amenable to biopsy and lack of contra-indications to FMT. Patients will undergo a baseline evaluation including imaging, tumor biopsy, blood samples and stool studies to confirm suitability for the study. Eligible patients will undergo FMT. The FMT includes a colonoscopy followed by stool capsules. Patients will undergo repeated evaluations including follow-up blood, stool and radiological testings. The study will be conducted over a 24-week period.
Interventions
PROCEDUREFecal Microbiota Transplant (FMT)
Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
Sponsors
Sheba Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A histologically confirmed diagnosis of metastatic melanoma. * Failed at least one line of PD-1 blockade. * ECOG Performance Status 0-2 * Able to provide written informed consent.
Exclusion criteria
* Presence of absolute contra-indications to FMT administration. * Severe dietary allergies (e.g. shellfish, nuts, seafood). * Anatomic contra-indications to colonoscopy. * Inability to swallow capsules. * Current participation in a study of an investigational agent. * Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (\> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy prior to trial treatment. * History of bleeding disorder, chronic kidney disease, Inflammatory bowel disease. * History of a major abdominal surgery * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of FMT-related Adverse Events | 4 years | Number of patients with adverse events that emerged post FMT |
| Proper implant engraftment | 4 years | Comparing of the patients' gut bacterial composition pre and post-FMT and in relation to their donors. Bacterial composition will be quantified by the operational taxonomic unit (OTU) in the stool |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in composition of immune cell population | 4 years | Changes in the relative abundance of different immune cell population (such as the proportion of CD8+ T cells) pre and post-FMT. |
| Changes in activity of immune cells | 4 years | Changes in levels of proteins that represent immune activity against cancer (such as measurements of blood interferon gamma levels), pre and post FMT |
Other
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | 4 years | Number of patients with objective responses divided by the total number of evaluable patients, according to imaging studies (RECIST 1.1) and iRECIST. |
Countries
Israel
Contacts
Primary ContactGal N Markel, MD,PhD
Backup ContactBen S Boursi, MD
Outcome results
None listed